Results 211 to 220 of about 4,461,549 (298)

Circulating Interleukin‐6 Levels and Timing of Acute Ischemic Stroke Onset

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Intravenous thrombolysis is the most widely available effective ischemic stroke treatment, but is approved only if given within 4.5 h from stroke onset. Many patients are not treated because stroke onset time is unknown. We evaluated the cytokine interleukin 6 (IL‐6) in circulating blood after acute ischemic stroke (AIS).
Robert G. Kowalski   +15 more
wiley   +1 more source

The evolution of male-female dominance relations in primate societies. [PDF]

open access: yesProc Natl Acad Sci U S A
Huchard E   +4 more
europepmc   +1 more source

Corrigendum: Characteristics of the vaginal microbiota and vaginal metabolites in women with cervical dysplasia

open access: yesFrontiers in Cellular and Infection Microbiology
Tiantian Yu   +7 more
doaj   +1 more source

Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We aimed to investigate the comparative effectiveness of standard versus personalized extended interval dosing of anti‐CD20 therapy on clinical and sub‐clinical outcomes in multiple sclerosis. Methods Clinical information was collected prospectively on Research Electronic Data Capture.
Nabil K. El Ayoubi   +6 more
wiley   +1 more source

Associations of Stroke With Risk of Epilepsy: Results From the Atherosclerosis Risk in Communities (ARIC) Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To estimate the risk of epilepsy associated with stroke in a community‐based cohort, with consideration of stroke type, number, and severity. Methods Data from 15,100 Atherosclerosis Risk in Communities (ARIC) Study participants without stroke at baseline (1987–1989) were analyzed through 12/31/2022.
Jiping Zhou   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy